Oxytocin

Summary

Oxytocin is a naturally occurring nonapeptide hormone synthesized in the hypothalamus and released from the posterior pituitary. As a pharmaceutical agent it is used to induce or augment labor, control postpartum hemorrhage, and stimulate milk let-down. It also has significant neuromodulatory roles and is under investigation for psychiatric indications including autism spectrum disorder and social anxiety.

Mechanism of Action

Binds to oxytocin G-protein coupled receptors (OTRs) on uterine smooth muscle, mammary gland myoepithelial cells, and CNS neurons, activating Gq/11 signaling, increasing intracellular calcium, stimulating uterine contractions, milk ejection, and modulating social bonding, trust, and stress responses.

Routes of Administration

Goals & Uses

• Milk ejection / lactation supportLactationModerate
• Social functioning improvement in autism spectrum disorderPsychiatric / InvestigationalLow
• Incomplete or inevitable abortion managementObstetricHigh
• Prevention and treatment of postpartum hemorrhageObstetricHigh
• Labor induction and augmentationObstetricHigh
• Anxiolytic / social anxiety reductionPsychiatric / InvestigationalLow

Contraindications

• Unfavorable fetal position or presentation undeliverable without interventionObstetricHigh
• Cephalopelvic disproportionObstetricHigh
• Hypersensitivity to oxytocinAllergy / ImmunologicHigh
• Hypertonic uterine contractionsObstetricHigh
• Prior classical uterine incision or uterine surgery with high rupture riskUterine IntegrityHigh
• Fetal distress without delivery being imminentFetal SafetyHigh

Adverse Effects

• Uterine hyperstimulation / tachysystoleUterineCommon
• AnaphylaxisImmunologicRareSevere life-threatening allergic reaction
• Hyponatremia / water intoxicationMetabolicUncommon
• Fetal heart rate abnormalitiesFetalCommon
• HypotensionCardiovascularCommonLow blood pressure
• Nausea and vomitingGastrointestinalCommon

Drug Interactions

• Vasoconstrictors / sympathomimetics (e.g., ephedrine, phenylephrine)Moderate
• Inhalational anesthetics (e.g., sevoflurane, isoflurane)Moderate
• Prostaglandins (e.g., misoprostol, dinoprostone)High
• Antidiuretic hormone (ADH) / desmopressinModerate
• QT-prolonging drugs (e.g., haloperidol, azithromycin)Moderate

Population Constraints

• Hyponatremia (pre-existing)ElectrolyteRelative
• Renal impairmentOrgan ImpairmentRelative
• Grand multiparityObstetric RiskRelative
• Cardiovascular diseaseCardiacRelative

Regulatory Status

• European UnionApprovedApproved: Induction of labor, Augmentation of dysfunctional labor, Prevention and treatment of postpartum uterine atony and hemorrhage, Milk ejection stimulationSyntocinon nasal spray remains authorized in several EU member states for lactation support. EMA oversight applies.
• United StatesApprovedApproved: Induction of labor, Augmentation of labor, Postpartum hemorrhage control, Incomplete or inevitable abortionPitocin (IV/IM formulation) is FDA-approved. Intranasal Syntocinon was voluntarily withdrawn from the US market by Novartis in 1997; not FDA-approved for psychiatric uses.
• United KingdomApprovedApproved: Induction of labor, Augmentation of labor, Prevention and treatment of postpartum hemorrhage, Incomplete abortion managementLicensed via MHRA; Syntocinon IV and nasal spray formulations available. Intranasal use for psychiatric indications remains unlicensed/off-label.

FDA-approved (Pitocin) for obstetric indications. Nasal spray formulation (Syntocinon) was FDA-approved but voluntarily withdrawn in the US market; remains available in other jurisdictions. Investigational intranasal use for psychiatric conditions is not FDA-approved.

Evidence & Sources

No sources recorded yet.